CHAPTER 9:Cationic Polysaccharides in Gene Delivery

Approval of Glybera®, a gene therapy to treat lipoprotein lipase deficiency, by the European Union Marketing Authorization, and more than 1800 clinical trials in over 31 countries for the treatment of many incurable diseases, narrates the successful journey of gene therapy in the biomedical field. However, the undesired side effects of gene therapy using viral and other vectors have overshadowed the success story of gene therapy. Non-viral vectors, and more particularly cationic polysaccharides due to their non-toxicity, water solubility, biodegradability and excellent compatibility with body systems, provide an excellent alternative for gene delivery. This chapter highlights significant contributions made by cationic polysaccharides in gene delivery.